Dr. Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service in Leeds and was awarded a Doctorate of Philosophy in 2002.
Dr. Rawstron's work into the understanding of CLL, both in terms of defining the nature of Monoclonal B-Lymphocytosis and in developing and standardizing the assessment of minimal residual disease (MRD) in CLL, has been internationally recognized. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research.
Dr. Rawstron has a "routine" service commitment in the development, selection and interpretation of relevant tests for the diagnosis, treatment and monitoring of haematological malignancy.
Within this role he has developed a National award-winning service for monitoring people with MGUS (monoclonal gammopathy of unknown significance) or early stage CLL.
Proposal to improve ESCCA: to facilitate the formation of collaborative groups within ESCCA aimed at developing harmonised clinical cytometry assays.